Ginkgo Bioworks, Inc.

Hill-rom Services, Inc.

Daniel Mccoy

Robert Mark Zerhusen

Richard Henry Heimbrock

Garrett E Berry

James Kennon Smith

David Dismuke

Sr Richard Joseph Schuman

The present disclosure provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a subject in vivo.

Virus vectors for targeting ophthalmic tissues

Antibody-evading virus vectors

AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein are described. Also described are methods of administering the virus vectors and virus capsids to a cell or to a subject in vivo.

Recombinant adeno-associated virus vectors

The present disclosure provides recombinant AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the recombinant AAV capsid proteins. The disclosure also provides methods of administering the virus vectors and vims capsids of the disclosure to a cell or to a subject in vivo.

Provided herein are gene therapy compositions and methods for treating, preventing, and/or curing NPC1. More specifically, the disclosure provides Adeno-associated virus (AAV) vectors for delivery of nucleic acids and nucleic acids (including AAV transfer cassettes) for treating, preventing, and/or curing NPC1.

Growing community of inventors

Durham, NC, United States of America

Daniel Mccoy